Sirion reports Durezol data

Sirion (Tampa, Fla.) said preliminary data showed that four-times-daily Durezol was noninferior to eight-times-daily Pred Forte prednisolone ophthalmic suspension in reducing anterior chamber cell grades, the primary endpoint, at day 14 in the Phase III ST-601A-001 trial to treat endogenous anterior uveitis. The six-week, double-blind, U.S. study of Sirion's topical ophthalmic emulsion containing difluprednate enrolled 90 patients. ...